Migdal Insurance & Financial Holdings Ltd. continued to hold its stake in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 397,920 shares of the biotechnology company’s stock at the close of the second quarter. Migdal Insurance & Financial Holdings Ltd. owned 2.32% of Redhill Biopharma worth $3,431,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in RDHL. Bank of New York Mellon Corp bought a new position in shares of Redhill Biopharma during the 1st quarter valued at about $101,000. Renaissance Technologies LLC increased its position in shares of Redhill Biopharma by 144.1% during the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock valued at $595,000 after purchasing an additional 36,600 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in shares of Redhill Biopharma by 36.5% during the 1st quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 6,172 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Redhill Biopharma during the 1st quarter valued at about $276,000. Finally, Family Management Corp bought a new position in shares of Redhill Biopharma during the 1st quarter valued at about $163,000. Hedge funds and other institutional investors own 10.99% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Redhill Biopharma Ltd. (RDHL) Holdings Maintained by Migdal Insurance & Financial Holdings Ltd.” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/08/redhill-biopharma-ltd-rdhl-holdings-maintained-by-migdal-insurance-financial-holdings-ltd.html.

Shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) traded down 3.23% during trading on Friday, hitting $9.58. The stock had a trading volume of 126,288 shares. Redhill Biopharma Ltd. has a 12 month low of $8.16 and a 12 month high of $14.74. The stock has a 50 day moving average of $8.97 and a 200 day moving average of $9.33. The company’s market cap is $164.42 million.

Redhill Biopharma (NASDAQ:RDHL) last released its earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The firm had revenue of $0.48 million during the quarter, compared to analysts’ expectations of $0.34 million. Equities analysts forecast that Redhill Biopharma Ltd. will post ($2.36) EPS for the current fiscal year.

RDHL has been the topic of several recent research reports. Roth Capital reiterated a “buy” rating and set a $27.00 price objective on shares of Redhill Biopharma in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective (up from $33.00) on shares of Redhill Biopharma in a research report on Wednesday. Zacks Investment Research upgraded Redhill Biopharma from a “hold” rating to a “buy” rating and set a $9.75 price objective on the stock in a research report on Tuesday, July 4th. FBR & Co reiterated a “buy” rating on shares of Redhill Biopharma in a research report on Friday, June 16th. Finally, Seaport Global Securities initiated coverage on Redhill Biopharma in a research report on Friday. They set a “buy” rating and a $19.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Redhill Biopharma has a consensus rating of “Buy” and a consensus price target of $23.35.

Redhill Biopharma Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Want to see what other hedge funds are holding RDHL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Redhill Biopharma Ltd. (NASDAQ:RDHL).

Institutional Ownership by Quarter for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Stock Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related stocks with our FREE daily email newsletter.